Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 107

1.

Impact of Graphene-Based Surfaces on the Basic Biological Properties of Human Umbilical Cord Mesenchymal Stem Cells: Implications for Ex Vivo Cell Expansion Aimed at Tissue Repair.

Jagiełło J, Sekuła-Stryjewska M, Noga S, Adamczyk E, Dźwigońska M, Kurcz M, Kurp K, Winkowska-Struzik M, Karnas E, Boruczkowski D, Madeja Z, Lipińska L, Zuba-Surma EK.

Int J Mol Sci. 2019 Sep 14;20(18). pii: E4561. doi: 10.3390/ijms20184561.

2.

Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial.

Mullane KM, Morrison VA, Camacho LH, Arvin A, McNeil SA, Durrand J, Campbell B, Su SC, Chan ISF, Parrino J, Kaplan SS, Popmihajlov Z, Annunziato PW; V212 Protocol 011 Trial Team.

Lancet Infect Dis. 2019 Sep;19(9):1001-1012. doi: 10.1016/S1473-3099(19)30310-X. Epub 2019 Aug 6. Erratum in: Lancet Infect Dis. 2019 Aug 23;:.

PMID:
31399378
3.

Costs Associated with Productivity Loss Among U.S. Patients Newly Diagnosed with Multiple Myeloma Receiving Oral Versus Injectable Chemotherapy.

Merola D, Yong C, Noga SJ, Shermock KM.

J Manag Care Spec Pharm. 2018 Oct;24(10):1019-1026. doi: 10.18553/jmcp.2018.24.10.1019.

4.

Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial.

Weinstein C, Jordan K, Green SA, Camacho E, Khanani S, Beckford-Brathwaite E, Pong A, Noga SJ, Rapoport BL.

Support Care Cancer. 2018 Nov;26(11):3773-3780. doi: 10.1007/s00520-018-4242-x. Epub 2018 May 28.

PMID:
29808377
5.

Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States.

Hari P, Romanus D, Palumbo A, Luptakova K, Rifkin RM, Tran LM, Raju A, Farrelly E, Noga SJ, Blazer M, Chari A.

Clin Lymphoma Myeloma Leuk. 2018 Feb;18(2):152-160. doi: 10.1016/j.clml.2017.12.012. Epub 2018 Jan 5.

6.

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.

Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J; ALCYONE Trial Investigators.

N Engl J Med. 2018 Feb 8;378(6):518-528. doi: 10.1056/NEJMoa1714678. Epub 2017 Dec 12.

7.

Factors associated with second-line triplet therapy in routine care in relapsed/refractory multiple myeloma.

Hari P, Romanus D, Henk HJ, Becker LK, Noga SJ, Morrison VA.

J Clin Pharm Ther. 2018 Feb;43(1):45-51. doi: 10.1111/jcpt.12606. Epub 2017 Aug 17.

PMID:
28833305
8.

Polylactide- and polycaprolactone-based substrates enhance angiogenic potential of human umbilical cord-derived mesenchymal stem cells in vitro - implications for cardiovascular repair.

Sekuła M, Domalik-Pyzik P, Morawska-Chochół A, Bobis-Wozowicz S, Karnas E, Noga S, Boruczkowski D, Adamiak M, Madeja Z, Chłopek J, Zuba-Surma EK.

Mater Sci Eng C Mater Biol Appl. 2017 Aug 1;77:521-533. doi: 10.1016/j.msec.2017.03.281. Epub 2017 Mar 30.

PMID:
28532062
9.

Treating Multiple Myeloma Patients With Oral Therapies.

Kumar SK, Vij R, Noga SJ, Berg D, Brent L, Dollar L, Chari A.

Clin Lymphoma Myeloma Leuk. 2017 May;17(5):243-251. doi: 10.1016/j.clml.2017.02.024. Epub 2017 Mar 7. Review.

PMID:
28347676
10.

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial.

Weinstein C, Jordan K, Green SA, Camacho E, Khanani S, Beckford-Brathwaite E, Vallejos W, Liang LW, Noga SJ, Rapoport BL.

Ann Oncol. 2016 Jan;27(1):172-8. doi: 10.1093/annonc/mdv482. Epub 2015 Oct 8.

11.

Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial.

Guo Y, Jones D, Palmer JL, Forman A, Dakhil SR, Velasco MR, Weiss M, Gilman P, Mills GM, Noga SJ, Eng C, Overman MJ, Fisch MJ.

Support Care Cancer. 2014 May;22(5):1223-31. doi: 10.1007/s00520-013-2075-1. Epub 2013 Dec 22.

12.

A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.

Berenson JR, Hilger JD, Yellin O, Boccia RV, Matous J, Dressler K, Ghazal HH, Jamshed S, Kingsley EC, Harb WA, Noga SJ, Nassir Y, Swift RA, Vescio R.

Ann Hematol. 2014 Jan;93(1):89-98. doi: 10.1007/s00277-013-1910-2. Epub 2013 Oct 18.

PMID:
24135804
13.

Retention Mechanism Studies of Selected Amino Acids and Vitamin B6 on HILIC Columns with Evaporative Light Scattering Detection.

Noga S, Jandera P, Buszewski B.

Chromatographia. 2013 Aug;76(15-16):929-937. Epub 2013 Jul 10.

14.

Hydrophilic interaction liquid chromatography columns classification by effect of solvation and chemometric methods.

Noga S, Bocian S, Buszewski B.

J Chromatogr A. 2013 Feb 22;1278:89-97. doi: 10.1016/j.chroma.2012.12.077. Epub 2013 Jan 10.

PMID:
23351397
15.

Hydrophilic interaction liquid chromatography and per aqueous liquid chromatography in fungicides analysis.

Noga S, Felinger A, Buszewski B.

J AOAC Int. 2012 Sep-Oct;95(5):1362-70.

PMID:
23175967
16.

Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.

Berenson JR, Yellin O, Bessudo A, Boccia RV, Noga SJ, Gravenor DS, Patel-Donnelly D, Siegel RS, Kewalramani T, Gorak EJ, Nassir Y, Swift RA, Mayo D.

Br J Haematol. 2013 Feb;160(3):321-30. doi: 10.1111/bjh.12129. Epub 2012 Nov 15.

PMID:
23150919
17.

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.

Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, Stewart AK, Turturro F, Rifkin R, Wolf J, Estevam J, Mulligan G, Shi H, Webb IJ, Rajkumar SV.

Blood. 2012 May 10;119(19):4375-82. doi: 10.1182/blood-2011-11-395749. Epub 2012 Mar 15.

PMID:
22422823
18.

In vivo Toll-like receptor 4 antagonism restores cardiac function during endotoxemia.

Ehrentraut S, Lohner R, Schwederski M, Ehrentraut H, Boehm O, Noga S, Langhoff P, Baumgarten G, Meyer R, Knuefermann P.

Shock. 2011 Dec;36(6):613-20. doi: 10.1097/SHK.0b013e318235805f.

PMID:
22089127
19.

Hydrophilic interaction liquid chromatography (HILIC)--a powerful separation technique.

Buszewski B, Noga S.

Anal Bioanal Chem. 2012 Jan;402(1):231-47. doi: 10.1007/s00216-011-5308-5. Epub 2011 Aug 31. Review.

20.

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.

Coiffier B, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, Rule S, Teixeira A, Walewski J, de Vos S, Crump M, Shpilberg O, Esseltine DL, Zhu E, Enny C, Theocharous P, van de Velde H, Elsayed YA, Zinzani PL; LYM-3001 study investigators.

Lancet Oncol. 2011 Aug;12(8):773-84. doi: 10.1016/S1470-2045(11)70150-4. Epub 2011 Jul 1.

PMID:
21724462

Supplemental Content

Loading ...
Support Center